20 new publications in Q2 2020

20 peer-reviewed publications have been published in Q2-2020 using Sophion QPatch or Qube 384. Read more about, among others, TMEM16 A and cystic fibrosis, drug-induced QT prolongation, NaV1.1 activators for epilepsy or antimicrobial peptides from a good broad variety of our users from among others Amgen, AbbVie, Acesion Pharma, Astellas Pharma, Evotec, Nanyang Technological University, and also five new publications from the University of Queensland and two Sophion authored publications.

Al-Sabi et Al. 2020. “Development of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves.” Bioorganic Chemistry 100(July 2019): 103918.

Chow et Al. 2020. “A Selective NaV1.1 Activator with Potential for Treatment of Dravet Syndrome Epilepsy.” Biochemical Pharmacology (February): 113991.

Diness et Al. 2020. “Inhibition of KCa2 Channels Decreased the Risk of Ventricular Arrhythmia in the Guinea Pig Heart During Induced Hypokalemia.” Frontiers in Pharmacology 11(May): 1–10.

Gonzales et Al. 2020. “Fluorescence Labeling of a NaV1.7-Targeted Peptide for near-Infrared Nerve Visualization.” EJNMMI Research 10(1): 49.

Henckels et Al. 2020. “Development of a QPatch-Automated Electrophysiology Assay for Identifying TMEM16A Small-Molecule Inhibitors.” ASSAY and Drug Development Technologies 18(3): 134–47.

Hirsch et Al. 2020. “Antimicrobial Peptides from Rat-Tailed Maggots of the Drone Fly Eristalis Tenax Show Potent Activity against Multidrug-Resistant Gram-Negative Bacteria.” Microorganisms 8(5): 626.

Israel et Al. 2020. “Characterization of Synthetic Tf2 as a NaV1.3 Selective Pharmacological Probe.” Biomedicines 8(6 Special Issue “Animal Venoms–Curse or Cure?”).

Koshman et Al. 2020. “Drug-Induced QT Prolongation: Concordance of Preclinical Anesthetized Canine Model in Relation to Published Clinical Observations for Ten CiPA Drugs.” Journal of Pharmacological and Toxicological Methods 103(February): 106871.

Kuramoto et Al. 2020. “Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced HERG Inhibitory Activity.” Chemical and Pharmaceutical Bulletin 68(5): 452–65.

Lacivita et Al. 2020. “Privileged Scaffold-Based Design to Identify a Novel Drug-like 5-HT7 Receptor-Preferring Agonist to Target Fragile X Syndrome.” European Journal of Medicinal Chemistry 199: 112395.

Liao et Al. 2020. “Design, Synthesis and Biological Activity of Novel 2,3,4,5-Tetra-Substituted Thiophene Derivatives as PI3Kα Inhibitors with Potent Antitumor Activity.” European Journal of Medicinal Chemistry 197: 112309.

McGivern et Al. 2020. “Ion Channels and Relevant Drug Screening Approaches.” SLAS DISCOVERY: Advancing the Science of Drug Discovery 25(5): 413–19.

McMahon et Al. 2020. “Pharmacological Activity and NMR Solution Structure of the Leech Peptide HSTX-I.” Biochemical Pharmacology: 114082.

Okumu et Al. 2020. “Novel Bacterial Topoisomerase Inhibitors Derived from Isomannide.” European Journal of Medicinal Chemistry 199: 112324.

Ong et Al. 2020. “Modulation of Lymphocyte Potassium Channel Kv1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin.” ACS Pharmacology & Translational Science: acsptsci.0c00035.

Qian et Al. 2020. “Screening Assay Protocols Targeting the Nav1.7 Channel Using Qube High-Throughput Automated Patch-Clamp System.” Current Protocols in Pharmacology 89(1): e74.

Rozenfeld et Al. 2020. “A Big Molecule Induces Schwann Cells in the Peripheral Nervous System Leading to Myelin Sheath Repair.” International journal of Diabetes & Endocrinology Research: 1–13.

Schupp et Al. 2020. “Electrophysiological Studies of GABAA Receptors Using QPatch II, the Next Generation of Automated Patch-Clamp Instruments.” Current Protocols in Pharmacology 89(1): e75.

Walsh 2020. “Screening Technologies for Inward Rectifier Potassium Channels: Discovery of New Blockers and Activators.” SLAS DISCOVERY: Advancing the Science of Drug Discovery 25(5): 420–33.

Zhu et Al. 2020. “Structural Optimization of Aminopyrimidine-Based CXCR4 Antagonists.” European Journal of Medicinal Chemistry 187: 111914.